# B4GALT2

## Overview
B4GALT2 is a gene that encodes the enzyme beta-1,4-galactosyltransferase 2, a type II transmembrane protein primarily located in the Golgi apparatus. This enzyme is a member of the beta-1,4-galactosyltransferase family and is involved in the glycosylation process, specifically catalyzing the transfer of galactose to N-acetylglucosamine residues to form beta-1,4 linkages. These linkages are crucial for the biosynthesis of glycoconjugates and glycoproteins, which play significant roles in cell-cell communication, protein stability, and immune response (Venkitachalam2016Biochemical; Almeida1997A). The B4GALT2 gene is characterized by its seven exons and multiple transcript variants, which encode different isoforms of the enzyme, each contributing to the synthesis of complex glycan structures essential for various cellular functions (Zhou2022Identification; Scott2016Exome). The enzyme's activity is particularly important in neural functions and diseases, as it synthesizes the internal β1,4Gal structure of the HNK-1 glycan (Kizuka2019Regulated).

## Structure
The B4GALT2 gene encodes a 372-amino acid polypeptide that includes an N-terminal cytoplasmic domain, a single transmembrane domain, and a catalytic domain facing the Golgi lumen (Scott2016Exome). The protein has three potential glycosylation sites, which are common post-translational modifications (Scott2016Exome). B4GALT2 is a type II transmembrane protein, typical of eukaryotic galactosyltransferases, with a short cytosolic segment, a single transmembrane domain, and a large luminal catalytic domain (Hennet2002The). 

The gene has seven exons and three transcript variants with unique first exons (1A, 1B, 1C), encoding two different isoforms. The only difference between these isoforms is a short N-terminal 29 amino-acid sequence (Scott2016Exome). B4GALT2 is part of the beta-1,4-galactosyltransferase family, which is involved in the biosynthesis of N-acetyllactosamine on N-glycans (Zhou2022Identification). The enzyme is responsible for synthesizing the internal β1,4Gal structure of the HNK-1 glycan, which is significant in neural functions and diseases (Kizuka2019Regulated). The protein's structure and function are crucial for its role in glycosylation processes, impacting various biological pathways.

## Function
The B4GALT2 gene encodes the enzyme beta-1,4-galactosyltransferase 2, which plays a critical role in the glycosylation processes within human cells. This enzyme is responsible for catalyzing the transfer of galactose from UDP-galactose to N-acetylglucosamine residues, forming a beta-1,4 linkage. This activity is essential for the biosynthesis of glycoconjugates and glycoproteins, which are crucial for cell-cell communication, protein stability, and immune response (Venkitachalam2016Biochemical; Almeida1997A).

B4GALT2 is a type II Golgi membrane-bound glycoprotein, indicating its activity occurs primarily in the Golgi apparatus, where it participates in post-translational modification and processing of proteins (Scott2016Exome). The enzyme's function is particularly important in the synthesis of specific glycoproteins and glycolipids, contributing to the formation of complex glycan structures that are essential for cellular functions such as cell adhesion, migration, and immune surveillance (Venkitachalam2016Altered).

In healthy human cells, B4GALT2 is involved in the synthesis of the first N-acetyllactosamine unit, which is distinct from the poly-N-acetyllactosamine chain extension typically associated with β4Gal-T1 (Almeida1997A). This specific role in glycosylation processes highlights its importance in maintaining normal cellular and organismal functions.

## Clinical Significance
Mutations and alterations in the B4GALT2 gene have been implicated in various clinical conditions. In colorectal cancer (CRC), mutations in B4GALT2 disrupt its post-translational modification pattern, leading to functional changes that may contribute to oncogenic signaling. These mutations can affect multiple proteins, similar to the impact of microRNA defects on gene expression, highlighting the role of glycosylation in cancer progression (Venkitachalam2016Altered).

The B4GALT2 c.909C>T variant has been studied in the context of platelet reactivity in individuals undergoing clopidogrel-based antiplatelet therapy. This variant is associated with significantly lower ADP-induced maximal platelet aggregation in patients receiving dual antiplatelet therapy with clopidogrel and aspirin, suggesting it as an independent genetic predictor of on-treatment platelet reactivity. However, it does not affect platelet reactivity in individuals receiving clopidogrel alone (Pallet2018Beta1).

In Huntington's disease, a decrease in B4GALT2 expression was observed in transgenic mouse models, indicating a potential link to the disease's pathology through glycolipid and ganglioside metabolism imbalances (Desplats2007Glycolipid). These findings suggest that B4GALT2 plays a role in various diseases through its involvement in glycosylation processes.


## References


[1. (Venkitachalam2016Biochemical) Srividya Venkitachalam, Leslie Revoredo, Vinay Varadan, Ryan E. Fecteau, Lakshmeswari Ravi, James Lutterbaugh, Sanford D. Markowitz, Joseph E. Willis, Thomas A. Gerken, and Kishore Guda. Biochemical and functional characterization of glycosylation-associated mutational landscapes in colon cancer. Scientific Reports, March 2016. URL: http://dx.doi.org/10.1038/srep23642, doi:10.1038/srep23642. This article has 45 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/srep23642)

[2. (Kizuka2019Regulated) Yasuhiko Kizuka. Regulated expression and disease relevance of neural glycans. Trends in Glycoscience and Glycotechnology, 31(181):SJ89–SJ90, July 2019. URL: http://dx.doi.org/10.4052/tigg.1942.2sj, doi:10.4052/tigg.1942.2sj. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.4052/tigg.1942.2sj)

[3. (Desplats2007Glycolipid) Paula A. Desplats, Christine A. Denny, Kristi E. Kass, Tim Gilmartin, Steven R. Head, J. Gregor Sutcliffe, Thomas N. Seyfried, and Elizabeth A. Thomas. Glycolipid and ganglioside metabolism imbalances in huntington’s disease. Neurobiology of Disease, 27(3):265–277, September 2007. URL: http://dx.doi.org/10.1016/j.nbd.2007.05.003, doi:10.1016/j.nbd.2007.05.003. This article has 117 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.nbd.2007.05.003)

4. (Pallet2018Beta1) Ref Pallet2018Beta1. This article has 3 citations and is from a peer-reviewed journal.

[5. (Zhou2022Identification) Zhiyang Zhou, Tao Wang, Yao Du, Junping Deng, Ge Gao, and Jiangnan Zhang. Identification of a novel glycosyltransferase prognostic signature in hepatocellular carcinoma based on lasso algorithm. Frontiers in Genetics, March 2022. URL: http://dx.doi.org/10.3389/fgene.2022.823728, doi:10.3389/fgene.2022.823728. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fgene.2022.823728)

[6. (Venkitachalam2016Altered) Srividya Venkitachalam and Kishore Guda. Altered glycosyltransferases in colorectal cancer. Expert Review of Gastroenterology &amp; Hepatology, 11(1):5–7, November 2016. URL: http://dx.doi.org/10.1080/17474124.2017.1253474, doi:10.1080/17474124.2017.1253474. This article has 17 citations.](https://doi.org/10.1080/17474124.2017.1253474)

[7. (Almeida1997A) Raquel Almeida, Margarida Amado, Leonor David, Steven B. Levery, Eric H. Holmes, Gerard Merkx, Ad Geurts van Kessel, Eske Rygaard, Helle Hassan, Eric Bennett, and Henrik Clausen. A family of human β4-galactosyltransferases. Journal of Biological Chemistry, 272(51):31979–31991, December 1997. URL: http://dx.doi.org/10.1074/jbc.272.51.31979, doi:10.1074/jbc.272.51.31979. This article has 142 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.272.51.31979)

[8. (Scott2016Exome) SA Scott, J‐P Collet, U Baber, Y Yang, I Peter, M Linderman, J Sload, W Qiao, AS Kini, SK Sharma, RJ Desnick, V Fuster, RJ Hajjar, G Montalescot, and J‐S Hulot. Exome sequencing of extreme clopidogrel response phenotypes identifies b4galt2 as a determinant of on‐treatment platelet reactivity. Clinical Pharmacology &amp; Therapeutics, 100(3):287–294, June 2016. URL: http://dx.doi.org/10.1002/cpt.401, doi:10.1002/cpt.401. This article has 20 citations.](https://doi.org/10.1002/cpt.401)

[9. (Hennet2002The) T. Hennet. The galactosyltransferase family. Cellular and Molecular Life Sciences (CMLS), 59(7):1081–1095, July 2002. URL: http://dx.doi.org/10.1007/s00018-002-8489-4, doi:10.1007/s00018-002-8489-4. This article has 157 citations.](https://doi.org/10.1007/s00018-002-8489-4)